• Welcome to Specialised Therapeutics

lurbinectedin - Specialised Therapeutics - Page 3

image_pdfimage_print
April 28, 2014
  • By stabioadmin
  • 0 Comments

STA to License New Drug – ILUVIEN® – to Improve Vision in Patients with Diabetes-Induced Vision Loss

Melbourne, Australia and Atlanta, Georgia, 28 April 2014: Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM). The exclusive agreement enables STA to distribute

Read More
March 5, 2014
  • By stabioadmin
  • 0 Comments

STA Receives TGA Approval for ABRAXANE® in Combination with Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer

Melbourne, Australia – March, 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved indication is: ABRAXANE, in combination with gemcitabine, is indicated for the first-line

Read More